Open AccessCost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective
Author(s) -
Bhavani Shankara Bagepally,
Usa Chaikledkaew,
Sitaporn Youngkong,
Thunyarat Anothaisintawee,
Montarat Thavorncharoensap,
Charungthai Dejthevaporn,
Ammarin Thakkinstian
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s328433
Subject(s) - dapagliflozin , medicine , metformin , type 2 diabetes mellitus , cost effectiveness , type 2 diabetes , pharmacotherapy , health economics , diabetes mellitus , intensive care medicine , endocrinology , public health , risk analysis (engineering) , nursing
Type 2 diabetes mellitus (T2DM) is a leading health issue, causing economic burden in India. Pharmacotherapy is a major cost driver in diabetic care usually funded through out of pocket expenditure; however, there has been a very limited economic evaluation evidence to guide the choice of diabetes pharmacotherapy in India. Therefore, this study aims to evaluate the long-term cost-effectiveness of dapagliflozin (sodium glucose transporter 2 inhibitor) compared to commonly used sulfonylureas as second-line drugs in Indian patients with T2DM.